Kohei Nakachi

3.3k total citations · 1 hit paper
51 papers, 1.7k citations indexed

About

Kohei Nakachi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kohei Nakachi has authored 51 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 18 papers in Surgery. Recurrent topics in Kohei Nakachi's work include Pancreatic and Hepatic Oncology Research (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers) and Hepatocellular Carcinoma Treatment and Prognosis (11 papers). Kohei Nakachi is often cited by papers focused on Pancreatic and Hepatic Oncology Research (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers) and Hepatocellular Carcinoma Treatment and Prognosis (11 papers). Kohei Nakachi collaborates with scholars based in Japan and United States. Kohei Nakachi's co-authors include Junji Furuse, Takuji Okusaka, Hiroshi Ishii, Masafumi Ikeda, Eiichiro Suzuki, Nobumasa Mizuno, S. Ohkawa, A Funakoshi, Satoshi Kondo and Soshi Nagaoka and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Kohei Nakachi

50 papers receiving 1.6k citations

Hit Papers

Gemcitabine alone or in combination with cisplatin in pat... 2010 2026 2015 2020 2010 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
    2010 541 citations Takuji Okusaka, Kohei Nakachi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kohei Nakachi Japan 18 970 831 659 324 309 51 1.7k
Lehua Shi China 19 819 0.8× 863 1.0× 664 1.0× 557 1.7× 293 0.9× 40 1.8k
Hirohiko Sakamoto Japan 18 1.3k 1.3× 705 0.8× 513 0.8× 224 0.7× 414 1.3× 88 1.9k
Birgit Gruenberger Austria 20 1.0k 1.1× 645 0.8× 475 0.7× 703 2.2× 122 0.4× 58 1.6k
Goro Watanabe Japan 19 552 0.6× 569 0.7× 507 0.8× 837 2.6× 480 1.6× 92 2.1k
Xinyu Bi China 17 480 0.5× 316 0.4× 289 0.4× 400 1.2× 216 0.7× 100 1.2k
Aris Polyzos Greece 19 1.2k 1.2× 267 0.3× 607 0.9× 215 0.7× 178 0.6× 55 1.5k
Anwaar Saeed United States 18 964 1.0× 386 0.5× 365 0.6× 87 0.3× 101 0.3× 167 1.4k
N Tanigawa Japan 25 868 0.9× 552 0.7× 638 1.0× 270 0.8× 116 0.4× 48 2.3k
Qiankun Xie China 17 483 0.5× 274 0.3× 200 0.3× 385 1.2× 184 0.6× 31 1.1k
Nathalie Guedj France 17 523 0.5× 498 0.6× 211 0.3× 286 0.9× 448 1.4× 52 1.3k

Countries citing papers authored by Kohei Nakachi

Since Specialization
Citations

This map shows the geographic impact of Kohei Nakachi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kohei Nakachi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kohei Nakachi more than expected).

Fields of papers citing papers by Kohei Nakachi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kohei Nakachi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kohei Nakachi. The network helps show where Kohei Nakachi may publish in the future.

Co-authorship network of co-authors of Kohei Nakachi

This figure shows the co-authorship network connecting the top 25 collaborators of Kohei Nakachi. A scholar is included among the top collaborators of Kohei Nakachi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kohei Nakachi. Kohei Nakachi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nakachi, Kohei, Masafumi Ikeda, Masaru Konishi, et al.. (2024). Adjuvant S-1 vs. observation for resected biliary tract cancer: 5-year follow-up of the JCOG1202/ASCOT.. Journal of Clinical Oncology. 42(16_suppl). 4119–4119. 1 indexed citations
2.
Ikeda, Masafumi, et al.. (2024). 330P Phase I/II clinical study of DFP-17729 as alkalizing agent in patients with metastatic pancreatic cancer. Annals of Oncology. 35. S139–S139. 1 indexed citations
3.
Kobayashi, Shogo, Kohei Nakachi, Masafumi Ikeda, et al.. (2022). Feasibility of adjuvant S-1 chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.. Journal of Clinical Oncology. 40(4_suppl). 408–408. 1 indexed citations
4.
Nakachi, Kohei, Masaru Konishi, Masafumi Ikeda, et al.. (2018). Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. International Journal of Clinical Oncology. 23(5). 894–899. 9 indexed citations
5.
Nakachi, Kohei, Masaru Konishi, Masafumi Ikeda, et al.. (2018). A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Japanese Journal of Clinical Oncology. 48(4). 392–395. 65 indexed citations
6.
Hagihara, Atsushi, Masafumi Ikeda, Hideki Ueno, et al.. (2014). Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Science. 105(3). 354–358. 9 indexed citations
7.
Sawada, Yu, Toshiaki Yoshikawa, Daisuke Nobuoka, et al.. (2012). Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. Clinical Cancer Research. 18(13). 3686–3696. 251 indexed citations
8.
Ito, Tetsuhide, Takuji Okusaka, H Igarashi, et al.. (2012). Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial. Japanese Journal of Clinical Oncology. 42(10). 903–911. 41 indexed citations
9.
Suzuki, Shinya, Yoshiko Nishimura, Satoshi Shimizu, et al.. (2011). Evaluation of Improvement of Adherence Following Pharmacist Intervention for Hand/Foot Skin Reactions Induced by Sorafenib. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 37(5). 317–321. 6 indexed citations
10.
Nakachi, Kohei, Izumi Ohno, Shino Shimizu, et al.. (2011). Clinical significance of elevation of the serum IL-6 level in patients with advanced pancreatic cancer.. Journal of Clinical Oncology. 29(4_suppl). 181–181. 1 indexed citations
11.
Iwasa, Satoru, Masafumi Ikeda, Takuji Okusaka, et al.. (2011). Transcatheter Arterial Infusion Chemotherapy with a Fine-powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Japanese Journal of Clinical Oncology. 41(6). 770–775. 27 indexed citations
12.
Takahashi, Shinichiro, Taira Kinoshitá, Masaru Konishi, et al.. (2011). Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. Journal of Hepato-Biliary-Pancreatic Sciences. 18(4). 567–574. 43 indexed citations
13.
Suzuki, Eiichiro, Junji Furuse, Masafumi Ikeda, et al.. (2010). Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases. Oncology. 79(1-2). 39–45. 26 indexed citations
14.
Furuse, Junji, Takuji Okusaka, Shuichi Kaneko, et al.. (2010). Phase I/II study of the pharmacokinetics, safety and efficacy of S‐1 in patients with advanced hepatocellular carcinoma. Cancer Science. 101(12). 2606–2611. 29 indexed citations
15.
Kawashima, Mitsuhiko, Ryosuke Kohno, Kohei Nakachi, et al.. (2010). Dose–Volume Histogram Analysis of the Safety of Proton Beam Therapy for Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 79(5). 1479–1486. 34 indexed citations
16.
Furuse, J., Takuji Okusaka, Kohei Nakachi, et al.. (2008). A phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Journal of Clinical Oncology. 26(15_suppl). 15556–15556. 2 indexed citations
17.
Morizane, Chigusa, Takuji Okusaka, Junji Furuse, et al.. (2006). A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Journal of Clinical Oncology. 24(18_suppl). 4115–4115. 3 indexed citations
18.
Furuse, Junji, Takuji Okusaka, Akihiro Funakoshi, et al.. (2006). Early Phase II Study of Uracil–Tegafur Plus Doxorubicin in Patients with Unresectable Advanced Biliary Tract Cancer. Japanese Journal of Clinical Oncology. 36(9). 552–556. 26 indexed citations
19.
Furuse, Junji, Hiroshi Ishii, Takuji Okusaka, et al.. (2005). Phase I Study of Fixed Dose Rate Infusion of Gemcitabine in Patients with Unresectable Pancreatic Cancer. Japanese Journal of Clinical Oncology. 35(12). 733–738. 8 indexed citations
20.
Ikoma, F, et al.. (1988). [Clinical evaluation of long-term administration of terodiline hydrochloride for the treatment of patients with pollakisuria and incontinence].. PubMed. 34(4). 724–32. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lehua Shi Breakdown of academic impact, for papers by Hirohiko Sakamoto Breakdown of academic impact, for papers by Birgit Gruenberger Breakdown of academic impact, for papers by Goro Watanabe Breakdown of academic impact, for papers by Xinyu Bi Breakdown of academic impact, for papers by Aris Polyzos Breakdown of academic impact, for papers by Anwaar Saeed Breakdown of academic impact, for papers by N Tanigawa Breakdown of academic impact, for papers by Qiankun Xie Breakdown of academic impact, for papers by Nathalie Guedj
Rankless by CCL
2026